You do not want to miss this one! We will issue this report on Thursday, May 5, 2022, at or near the market open.

Good day everyone,

Stocks have been volatile in recent weeks, with every day seeing the equities markets move in directions unknown. Between the war in Ukraine, high inflation Fed policy, and recession fears, it’s been difficult for investors to rationalize putting more money into the market.

But there’s one group investing in stocks without hesitation, and I expect them to start buying. Corporate profits have been strong, and some companies are flush with cash. Even though stock buybacks are getting some public and political scrutiny, many companies are planning to buy their own shares pumping hundreds of millions into the equities market.

I saw a headline this morning indicating that investors were “bracing” themselves ahead of the Fed decision this week. I tend to doubt that because anyone that reads articles about the Fed already knows there will be interest rate hikes coming throughout this year.

I want to talk to you about a NASDAQ company in the biopharma sector. The sector has been hammered by the overall stock market decline making it an easy task to find companies that look oversold, and our new report will look at one.

This company has several products in its drug pipeline in various stages of development, but we will focus on one of them that has blockbuster potential. This one product is in a phase III clinical trial and all indications are completion of clinical trials by the end of this year. When I look at the chart setup, consider the market for this product, and look at the current value of the company I see an irresistible opportunity for a near term swing.

Stay tuned and stay informed. We will issue this report on Thursday, May 5, 2022, at or near the market open.

The Traders News Group